Drug Discovery World

MAY 6, 2024

billion) Healthcare Innovation 2030 project, with ambitious plans to turn France into the European leader in health innovation by 2030. Since the launch of Healthcare Innovation 2030, investment has continued apace in the region. billion ($7.9 More than 400 companies now make up Lithuania’s life sciences sector 4.

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

Drug Discovery World

JANUARY 2, 2024

More significantly, she says, with the boost from what we have learned from Covid, cancer vaccines will become a reality. She believes we might start to see a combination of vaccines with other immunotherapies or classical therapies out there, and that this will become more and more prevalent because of the nature of cancer.

Research 147

Research Vaccine Science Trials 147

The Pharma Data

MAY 4, 2021

” “Even as the world makes progress on vaccine roll-outs, it remains vital for treatments to be available that can make a meaningful difference for those fighting COVID-19,” said David A. About OLUMIANT ® (baricitinib) OLUMIANT, a once-daily, oral JAK inhibitor was discovered by Incyte and licensed to Lilly.

Therapies 52

Therapies Hospitals FDA Approval Long-Term Care Facilities 52

Drug Discovery World

APRIL 25, 2024

billion in 2022, a figure that is expected to grow at a compound annual growth rate (CAGR) of 9.81% from 2023 to 2030 1. One of the most recent drivers of the cell line development market came from the Covid-19 pandemic, where research into vaccines skyrocketed and demand for cell lines was boosted as a result.

Vaccine 147

Vaccine Production Pharmaceuticals Therapies 147

The Pharma Data

JANUARY 9, 2021

• Anthrax Vaccines. Anthrax vaccine revenues are expected to be at a more normalized annual level and continue to primarily reflect procurement of AV7909 (Anthrax Vaccine Adsorbed, adjuvanted) under the Company’s existing contract with the Biomedical Advanced Research and Development Authority (BARDA).

Government 52

Government Vaccine Production Licensing 52

The Pharma Data

JULY 11, 2021

Phase 3 study met primary and secondary endpoints demonstrating MenQuadfi ® induced superior immune responses to serogroup C compared to a standard-of-care vaccine in healthy toddlers MenQuadfi is the first and only quadrivalent ACWY vaccine to demonstrate superior immune response against serogroup C in toddlers.

Immune Response 52

Immune Response Disease Vaccine Licensing 52

The Pharma Data

FEBRUARY 8, 2021

Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. to €36,041 million, driven by Dupixent ® (€3,534 million, up 73,9%) and Vaccines. We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks.

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52